Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy Mu Opioid Receptor (MOR) Agonist/Delta Opioid Receptor (DOR) Antagonist Ligands

We have previously described opioid peptidomimetic, 1, employing a tetrahydroquinoline scaffold and modeled on a series of cyclic tetrapeptide opioid agonists. We have recently described modifications to these peptides that confer a mu opioid receptor (MOR) agonist, delta opioid receptor (DOR) antag...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mosberg, Henry I., Yeomans, Larisa, Harland, Aubrie A., Bender, Aaron M., Sobczyk-Kojiro, Katarzyna, Anand, Jessica P., Clark, Mary J., Jutkiewicz, Emily M., Traynor, John R.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3618660/
https://ncbi.nlm.nih.gov/pubmed/23419026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm400050y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares